ALK and non-small cell lung carcinoma: It is now a standard recommendation that patients with advanced NSCLC undergo routine molecular testing for identification of certain known genomic abnormalities, most notably ALK rearrangements, EGFR mutations, BRAF V600E, ROS1 rearrangements, and NTRK fusions [5].